RxDoctor Payments Data

Christopher Simmons, MD

Internal Medicine · Lafayette, CANPI 1083630081

Payments from drug & device makers

$1,820in general payments, 2019–2025

Across 100 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$398
  • Amarin Pharma, Inc.$225
  • Johnson & Johnson$188
  • Boehringer Ingelheim$183
  • Radius Health, Inc.$145
  • Novo Nordisk$131
  • plus $550 from 16 others

What the payments were for

  • Food & beverage$1,77397%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,820 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$179,469
Medicare patients
275
Services billed
1,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$170,545
Repatha SureclickEvolocumab71$77,191
JardianceEmpagliflozin61$62,803
OzempicSemaglutide52$59,415
XareltoRivaroxaban26$30,730
EntrestoSacubitril/Valsartan37$29,074
LinzessLinaclotide35$25,926
MounjaroTirzepatide18$23,564
MyrbetriqMirabegron22$23,041
FarxigaDapagliflozin Propanediol16$17,075
NexletolBempedoic Acid18$13,134
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,131
TrulicityDulaglutide11$10,418
Rosuvastatin Calcium444$8,273
PaxlovidNirmatrelvir/Ritonavir55$4,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$398$174,710229 claims
Boehringer IngelheimJardiance$183$62,80361 claims
Novo NordiskOzempic$131$59,41552 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$93$36,51755 claims
Johnson & JohnsonXarelto$188$30,73026 claims
AbbVieLinzess, Synthroid$76$27,66567 claims
Astellas Pharma US IncMyrbetriq$22$23,04122 claims
AstraZenecaFarxiga$19$17,07516 claims
GSKTrelegy Ellipta$50$13,13117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lafayette

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →